US Edition
AstraZeneca Good Pre-Congress Prospects ASCO
Summary by Merca2.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
The British pharmaceutical company AstraZeneca will arrive at the American Society of Clinical Oncology (ASCO) 2025 event in its best form. On the one hand, AplhaValue analysts have raised their target price to six months from 11,284 to 12,057 pounds sterling with the recommendation of Purchasing. On the other hand, Berenberg analysts have reiterated their note of Purchasing with a target price of 14.00 pounds. Specifically, Abhishek Raval of Al…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
